What is a typical total intravenous anesthesia (TIVA) protocol for an adult patient undergoing general anesthesia?

TIVA Protocol for Adult General Anesthesia

A typical TIVA protocol for adult patients undergoing general anesthesia consists of propofol for hypnosis combined with remifentanil for analgesia, delivered via target-controlled infusion (TCI) or weight-based continuous infusion, with mandatory processed EEG monitoring when neuromuscular blocking drugs are used. 1

Core Drug Regimen

Induction

• Propofol: 1.5-2.5 mg/kg IV bolus OR TCI effect-site concentration of 4-6 μg/ml 2, 3
• Opioid options:
  • Remifentanil: 0.5 μg/kg/min for first minute, then 0.25 μg/kg/min 4
  • Fentanyl: 0.5-1 μg/kg bolus 2
  • Alfentanil: 5 μg/kg bolus 2

Maintenance

Standard propofol-remifentanil protocol (most common):

• Propofol TCI: Effect-site concentration 3-5 μg/ml (adjust based on pEEG monitoring) 5, 3
• Remifentanil TCI: Effect-site concentration 1-3 ng/ml, titrated in 0.05 μg/kg/min increments 2, 4

Memory aid for dosing ("4321" formula for propofol with fentanyl/alfentanil; "42222111" for propofol with remifentanil) 3

Neuromuscular Blockade

• Rocuronium: 1 mg/kg (preferred over succinylcholine for TIVA) 6, 7
• Avoid succinylcholine in specific populations (e.g., muscular dystrophy - absolutely contraindicated) 8
• Quantitative neuromuscular monitoring mandatory throughout - target train-of-four ratio >0.9 before extubation 1, 9

Essential Monitoring Requirements

Mandatory monitoring for TIVA 1:

• ECG, SpO₂, NIBP - started before induction
• Capnography - continuous waveform monitoring from induction through recovery
• Processed EEG monitoring (BIS/Entropy) - required when TIVA is combined with neuromuscular blocking drugs, started before induction and continued until full neuromuscular recovery confirmed 1

The 2021 Association of Anaesthetists guidelines explicitly state that pEEG monitoring "should be used when total intravenous anaesthesia (TIVA) is administered together with a NMB drug" to prevent accidental awareness 1. This addresses the critical safety concern that without volatile agent monitoring, depth of anesthesia assessment relies heavily on processed EEG when paralysis masks clinical signs.

Critical Safety Protocols

Intravenous Access

• Secure, dedicated IV line mandatory - maintain vascular access throughout procedure and until no longer at risk for cardiorespiratory depression 10
• If IV becomes dislodged during TIVA, immediately reestablish access 10
• Use anti-siphon valves and clearly label all syringes with drug name and concentration 5, 11

Drug Delivery

• Administer in small incremental doses or continuous infusion - titrate to effect 10
• Allow sufficient time between doses for peak effect assessment 10
• Use real-time pharmacokinetic simulations to visualize drug concentrations 11
• Avoid bolus dosing of propofol during maintenance (risk of oversedation/hypoventilation, especially with concurrent opioids) 2

Awareness Prevention

High-risk situations requiring extra vigilance 3, 12:

• "Triple low" patients (low BP, low propofol concentration, low body weight ≤18 kg)
• Obese patients
• Difficult IV access monitoring
• Emergency surgery with altered physiology

Adjunctive Medications

Multimodal Analgesia

• Dexamethasone: 8 mg IV at induction (reduces PONV and postoperative pain) 13
• Ketamine: 0.5 mg/kg bolus after induction, then 0.125-0.25 mg/kg/h infusion (stop 30 min before end of surgery) - for high-risk pain procedures or opioid-tolerant patients 13
• IV lidocaine: 1-2 mg/kg bolus, then 1-2 mg/kg/h infusion for major abdominal/pelvic/spinal surgery without regional analgesia 13

PONV Prophylaxis

TIVA with propofol significantly reduces PONV compared to volatile anesthetics (20% vs 38.3% incidence) 14, 4. Still ensure antiemetics available as rescue therapy 10.

Recovery Advantages

TIVA demonstrates superior early recovery parameters 14:

• Faster extubation time (7.4 vs 9.6 minutes with sevoflurane)
• Quicker Aldrete ≥9 recovery (23.1 vs 29.2 minutes)
• Shorter PACU stay (40 vs 50 minutes median)
• Higher 24-hour quality of recovery scores
• 66.7% of TIVA patients can bypass PACU-I entirely 15

Common Pitfalls to Avoid

1. Delivery errors: Most accidental awareness and cardiac arrests during TIVA result from preventable dosing/delivery errors 12. Use structured protocols and clear team roles.

2. Inadequate monitoring: Never rely solely on a single EEG index - assess depth comprehensively using multiple parameters including hemodynamics, pupil size, and movement 11

3. Re-sedation risk: Avoid casual administration of antagonists at emergence; patients require careful observation before ward transfer 11

4. Equipment failure: Have immediate backup plan to switch to inhalational anesthesia if TIVA delivery fails 5, 11

5. Emergency situations: TIVA in rapid sequence induction requires specific adaptations and validation - absence of emergency-specific guidelines means extra caution needed 12

Institutional Requirements

Facilities using TIVA must ensure 5, 11:

• Adequate training programs for all practitioners
• Standardized preparation protocols for drug dilution and labeling
• Reliable syringe pump systems
• Immediate availability of backup inhalational anesthesia
• Clear documentation systems (preferably automated electronic records) 1